Oxigene May 2026

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)

Despite promising science, the company faced periodic financial restructurings, including a significant workforce reduction in 2011 to conserve resources for early-stage programs. Oxigene

On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN). Acute Myeloid Leukemia (AML)

In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline Myelodysplastic Syndromes (MDS) Despite promising science

Lead candidate; received and Orphan Drug designations for platinum-resistant ovarian cancer. OXi4503